Foravirumab

Foravirumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	rabies virus glycoprotein
Clinical data
ATC code	none
Identifiers
CAS Number	944548-38-3^N
ChemSpider	none
UNII	377VY97V7S
ChEMBL	ChEMBL1743021^N
Chemical and physical data
Formula	C₆₄₀₀H₉₉₁₄N₁₇₁₈O₁₉₉₈S₄₄
Molar mass	144304.38 g·mol⁻¹
^NY (what is this?) (verify)

Foravirumab is a monoclonal antibody for the prophylaxis of rabies.^[1] It is under development by Sanofi/Crucell.^[2]

References

↑ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
↑ Khardori NM (2011). Biologic Response Modifiers in Infectious Diseases, An Issue of Infectious Disease Clinics. London: Elsevier Health Sciences. p. 158. ISBN 978-1-4557-1207-6.

Monoclonal antibodies for infectious disease and toxins

Human	Efungumab^†

Human	Ansuvimab Atoltivimab (+maftivimab/odesivimab) Bamlanivimab^† (+etesevimab)^† Bebtelovimab^§ Casirivimab^† (+imdevimab) Cilgavimab^† (+tixagevimab)^† Diridavumab^§ Etesevimab^† Exbivirumab^§ Foravirumab^§ Imdevimab^† (+casirivimab) Libivirumab^§ Maftivimab Odesivimab Rafivirumab^§ Regavirumab^§ Regdanvimab Sevirumab^† Sotrovimab Suptavumab Tixagevimab^† (+cilgavimab)^† Tuvirumab^§ Nirsevimab^†
Chimeric	Cosfroviximab Larcaviximab Porgaviximab
Humanized	Felvizumab^§ Lenvervimab^† Motavizumab^† Palivizumab Suvizumab^§

Bacterial

Human	Nebacumab Panobacumab^§ Raxibacumab
Mouse	Edobacomab^§
Chimeric	Pagibaximab^†
Humanized	Tefibazumab^†

Human	Actoxumab^§ Bezlotoxumab Suvratoxumab
Chimeric	Obiltoxaximab
Humanized	Urtoxazumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.